FHTX Earnings & Financial Statements
Foghorn Therapeutics Inc.
$1.87
+$0.02(+1.08%)
33
Overall
40
Value
9
Tech
52
Quality
Market Cap
$109.86M
Volume
9.79K
52W Range
$1.79 - $7.61
Target Price
$6.57
FHTX earnings and financial statements: Foghorn Therapeutics Inc.'s income statement, balance sheet and cash flow statement, annual and quarterly.
FHTX Annual Financial Statements
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | $30.91M | $22.60M | $34.16M | $19.23M | $1.32M |
| Operating income | -$86.39M | -$102.68M | -$107.91M | -$117.14M | -$100.73M |
| EBITDA | -$70.98M | -$83.48M | -$90.67M | -$113.82M | -$96.03M |
| Net income | -$74.30M | -$86.60M | -$98.40M | -$108.88M | -$101.32M |
| EPS (diluted) | $-1.18 | $-1.58 | $-2.34 | $-2.62 | $-2.73 |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total assets | $198.10M | $283.98M | $285.92M | $404.88M | $519.77M |
| Total liabilities | $306.60M | $329.51M | $363.11M | $404.77M | $422.90M |
| Shareholders’ equity | -$108.50M | -$45.53M | -$77.19M | $112.0K | $96.87M |
| Cash and equivalents | $80.88M | $55.45M | $80.34M | $52.21M | $101.14M |
| Long-term debt | $40.35M | $28.06M | $36.55M | $45.54M | $51.34M |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating cash flow | -$86.10M | -$100.41M | -$118.11M | $193.61M | -$50.25M |
| Capital expenditure | -$50.0K | -$906.0K | -$1.22M | -$1.21M | -$3.31M |
| Free cash flow | -$86.15M | -$101.31M | -$119.33M | $192.40M | -$53.56M |
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | FHTX | $1.87 | +1.1% | 9.79K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Foghorn Therapeutics Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW